Company / Capital Expenditures
Celldex Therapeutics, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.7M
FY2025
5-year range
$1.2M / $2.7M
FY2021-FY2025
Trend
+41.4%
vs FY2024
Sector context
#137 of 150
Health Care
What the data says
Among 150 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 9% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $731,000 in FY2019 to $3M in FY2018.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of +11.8%.
Improved from $2M to $3M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +14.1%
- 5-Year CAGR
- +11.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 150This company $2.7M Sector average $271.1M
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.8%, indicating consistent growth.
- In FY2025, capital expenditures increased 41.4% year-over-year.
- Ranks #137 out of 150 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.7M | +41.4% |
| FY2024 | $1.9M | +5.6% |
| FY2023 | $1.8M | -0.5% |
| FY2022 | $1.8M | +46.4% |
| FY2021 | $1.2M | -19.5% |
| FY2020 | $1.6M | +112.3% |
| FY2019 | $731.0K | -73.4% |
| FY2018 | $2.8M | +53.9% |
| FY2017 | $1.8M | -35.0% |
| FY2016 | $2.8M | -43.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026